Crizotinib has demonstrated superior response rates and PFS compared with chemotherapy [8, 20] and the median overall survival (OS) of ALK-positive NSCLC cases treated with crizotinib may be more than 5 years [21]. Here, ALK is linked to non-small cell lung carcinoma.